Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale

This publication has 29 references indexed in Scilit:

• Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range
  Circulation, 2008
• Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation
  Circulation: Cardiovascular Quality and Outcomes, 2008
• Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk
  Stroke, 2008
• ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation
  Circulation, 2006
• 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
  Bioorganic & Medicinal Chemistry Letters, 2006
• Review of the rebound phenomenon in new anticoagulant treatments
  Current Medical Research and Opinion, 2006
• Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial
  The Lancet, 2003
• Present treatment options for atrial fibrillation
  Published by Oxford University Press (OUP) ,2003
• An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial Infarction
  New England Journal of Medicine, 1993
• Probability of stroke: a risk profile from the Framingham Study.
  Stroke, 1991